A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514635-26-00

Acronym

NBK151/1/2022

Enrollment

Registered

2024-11-05

Start date

2025-08-28

Completion date

Unknown

Last updated

2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatoblastoma and liver cancer (hepatocarcinoma)

Brief summary

Depend on the Study Group: event-free survival, overall survival, adherence to surgical guidelines, chemotherapy-related toxicity, hearing loss, response, failure-free survival, surgical resectability.

Interventions

DRUGIRINOTECAN

DRUGOXALIPLATIN

DRUGPedmark

DRUGCISPLATIN

DRUGCARBOPLATIN

DRUGFLUOROURACIL

DRUGSORAFENIB

DRUGDOXORUBICIN

DRUGETOPOSIDE

DRUGVINCRISTINE

DRUGGEMCITABINE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Depend on the Study Group: event-free survival, overall survival, adherence to surgical guidelines, chemotherapy-related toxicity, hearing loss, response, failure-free survival, surgical resectability.	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026